Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CorMedix (CRMD) EBITDA (2016 - 2025)

Historic EBITDA for CorMedix (CRMD) over the last 14 years, with Q3 2025 value amounting to $8205.0.

  • CorMedix's EBITDA rose 14210.68% to $8205.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$17.9 million, marking a year-over-year decrease of 8380.65%. This contributed to the annual value of -$17.9 million for FY2024, which is 6129.01% up from last year.
  • CorMedix's EBITDA amounted to $8205.0 in Q3 2025, which was up 14210.68% from -$5121.0 recorded in Q2 2025.
  • CorMedix's EBITDA's 5-year high stood at $8205.0 during Q3 2025, with a 5-year trough of -$17.9 million in Q4 2024.
  • Its 5-year average for EBITDA is -$6.0 million, with a median of -$7.1 million in 2021.
  • Over the last 5 years, CorMedix's EBITDA had its largest YoY gain of 14210.68% in 2025, and its largest YoY loss of 32559.47% in 2025.
  • Quarter analysis of 5 years shows CorMedix's EBITDA stood at -$7.8 million in 2021, then dropped by 4.78% to -$8.2 million in 2022, then decreased by 19.32% to -$9.8 million in 2023, then tumbled by 83.87% to -$17.9 million in 2024, then soared by 100.05% to $8205.0 in 2025.
  • Its EBITDA was $8205.0 in Q3 2025, compared to -$5121.0 in Q2 2025 and -$6090.0 in Q1 2025.